Scope Biosciences B.V., a deep tech spin-off from Wageningen University & Research, has secured a follow-on investment from SHIFT Invest and Oost NL. The additional funding follows on the company’s strong progression and first significant commercial traction.
Including this new capital, together with a previously awarded €2.5 million EIC Transition Grant and earlier investments, ScopeBio has now secured a total of €6 million in seed-stage funding, combining strategic and venture capital investments with non-dilutive support from leading European and Dutch innovation programs.
scopeDx®: Bringing diagnostics out of the lab
At the heart of ScopeBio’s mission is a next-gen CRISPR-based molecular diagnostics platform — scopeDx® — that delivers ultra-precise, single-nucleotide detection in a format that’s portable and field-ready without proprietary hardware or centralized labs. The scopeDx® technology allows diagnostics to be performed closer to the source — in the field, at the point of care, or directly within agricultural operations. In agriculture, this enables earlier and more effective detection of crop diseases, helping to reduce losses and improve yields. In healthcare, it contributes to faster and broader access to reliable testing, especially in areas where centralized laboratories are not available.
Regional innovation with global impact
ScopeBio is headquartered on the Wageningen Campus and is embedded in the vibrant innovation ecosystem of the East Netherlands region. Maureen Haverkamp, Investment Manager at Oost NL: “ScopeBio’s technology aligns perfectly with our ambition to foster regional innovation with global relevance. We are proud to support this pioneering company as it enters its next growth phase.”
“We are proud to provide our continued support to ScopeBio. Over the past couple of years, we have closely followed ScopeBio’s progress in commercializing their highly accurate, on-site diagnostic platform in agriculture. We are excited to see the team tackling the healthcare market with the same level of determination,” said Sophie van Weede, Associate at SHIFT Invest.